文献速递胸部肿瘤支持与姑息治疗

免疫调节性合并用药对晚期癌症免疫检查点抑制剂疗效的影响及预后指数构建与验证

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
PubMed 文献 · Eur J Cancer · 2020-11-16

研究在单中心217例晚期癌症患者中评估基线合并用药对免疫检查点抑制剂(ICI)疗效的影响,构建基于药物的预后评分,并在多中心1012例外部队列中验证。结果显示皮质激素、全身抗生素和质子泵抑制剂(PPI)与总生存(OS)显著相关,评分可区分预后并区分OS、无进展生存(PFS)和客观缓解率(ORR)。

要点

  • 基线皮质激素、全身抗生素和PPI与ICI治疗患者OS显著相关。
  • 基于三类药物的预后评分可区分良好、中等和不良预后。
  • 评分在训练队列和外部队列中均显著区分OS、PFS和ORR。

核心结论

  • 累积暴露于皮质激素、抗生素和PPI(三种可能调节微生物群的药物)导致ICI治疗后结局逐步变差。
  • 提出一个简单评分,可帮助在常规实践和ICI临床试验中对患者进行分层。

研究设计与样本

  • 单中心训练队列纳入217例接受ICI治疗的晚期癌症患者,评估基线合并用药对ORR、PFS和OS的影响并构建药物预后评分。
  • 多中心外部队列纳入1012例患者用于外部验证该评分。

主要发现

  • 训练队列中位年龄69岁(范围32-89),原发肿瘤为非小细胞肺癌(70%)、黑色素瘤(14.7%)、肾细胞癌(9.2%)和其他(6%)。
  • 基线皮质激素与OS显著相关(HR=2.3;95%CI:1.60-3.30)。
  • 基线全身抗生素与OS显著相关(HR=2.07;95%CI:1.31-3.25)。
  • 基线PPI与OS显著相关(HR=1.57;95%CI:1.13-2.18)。
  • 训练队列中评分分层显著区分OS(p<0.0001)、PFS(p<0.0001)和ORR(p=0.0297);外部队列中评分显著区分OS(p<0.0001)、PFS(p<0.0001)和ORR(p=0.0006)。

关键数值与推荐

  • 预后评分基于皮质激素、全身抗生素和PPI三类药物计算,定义良好、中等和不良预后患者。

临床怎么用

  • 在ICI治疗前评估基线皮质激素、抗生素和PPI使用,可辅助预后分层。
  • 该评分可用于常规实践和临床试验中的患者分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications to create a drug-based prognostic score. METHODS: We evaluated concomitant baseline medications at immunotherapy initiation for their impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in a single-institution cohort of patients with advanced cancer treated with ICIs (training cohort, N = 217), and a drug-based prognostic score with the drugs resulting significantly impacting the OS was computed. Secondly, we externally validated the score in a large multicenter external cohort (n = 1012). RESULTS: In the training cohort (n = 217), the median age was 69 years (range: 32-89), and the primary tumours were non-small-cell lung cancer (70%), melanoma (14.7%), renal cell carcinoma (9.2%) and others (6%). Among baseline medications, corticosteroids (hazard ratio [HR] = 2.3; 95% confidence interval [CI]: 1.60-3.30), systemic antibiotics (HR = 2.07; 95% CI: 1.31-3.25) and proton-pump inhibitors (PPIs) (HR = 1.57; 95% CI: 1.13-2.18) were significantly associated with OS. The prognostic score was calculated using these three drug classes, defining good, intermediate and poor prognosis patients. Within the training cohort, OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0297) were significantly distinguished by the score stratification. The prognostic value of the score was also demonstrated in terms of OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0006) within the external cohort. CONCLUSION: Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy. We propose a simple score that can help stratifying patients in routine practice and clinical trials of ICIs.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Buti S, Bersanelli M, Perrone F, et al. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer. 2020. PMID: 33212418. doi:10.1016/j.ejca.2020.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。